ClinicalTrials.gg
CompletedNCT06677996Updated May 11, 2025

A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants

A Phase 1 interventional study of varegacestat and Itraconazole (200 mg) in Healthy Volunteer, sponsored by Immunome, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by Immunome, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is an open label, fixed sequence, 1-way crossover drug-drug interaction (DDI) study in healthy participants.

Read the detailed description

This is a phase 1, open-label, fixed sequence, 1-way crossover study examining the effect of itraconazole on the pharmacokinetics, safety and tolerability after varegacestat single dose administration to healthy participants. This is a 2-period study. In period 1 a single dose of varegacestat will be administered with PK evaluated predose and up to 192 hours postdose. There will be a 14 -day washout between period 1 and period 2. In period 2, itraconzole will be administered once daily for 18 consecutive days. Beginning on Day 4 of Period 2 a single dose of varegacestat will be administered 30 minutes after itraconazole dosing. Blood samples for PK will be collected prior to varegacestat dosing and up to 744 hours post varegacestat dosing for varegacestat and its metabolite.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Drug-Drug Interaction
  • Pharmacokinetics
03

In context

Lead sponsor

Immunome, Inc. is the lead sponsor of 11 studies on the registry; 5 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, adult, male or female (of non- only), 18 to 55 years of age, inclusive, at the screening visit.
  • Medically healthy with no medical history, physical examination, clinical laboratory profiles, vital signs, and ECGs, as deemed by the PI or designee

Exclusion criteria

Exclusion Criteria:

  • Mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  • History or presence of medical or psychiatric condition or disease in the opinion of the PI or designee.
  • History of any illness that, in the opinion of the PI or designee might confound the results of the study or poses an additional risk to the participant by their participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    Period 1: varegacestat administration for PK followed by Period 2: itraconazole and varegacestat administration for PK and DDI

    Drug: varegacestat · Drug: Itraconazole (200 mg)

Interventions

06

What researchers measure

Primary outcomes

  1. Effect of itraconazole on the PK of varegacestat in healthy participants.

    AUC0-t for varegacestat administered with and without itraconazole.

    Time frame: Up to 5 weeks

  2. Effect of itraconazole on the PK of varegacestat in healthy participants.

    AUC0-inf for varegacestat administered with and without itraconazole.

    Time frame: Up to 5 weeks

  3. Effect of itraconazole on the PK of varegacestat in healthy participants.

    Cmax for varegacestat administered with and without itraconazole.

    Time frame: Up to 5 weeks

  4. Effect of itraconazole on the PK of varegacestat in healthy participants.

    Tmax for varegacestat administered with and without itraconazole.

    Time frame: Up to 5 weeks

Secondary outcomes

  1. Safety and tolerability of varegacestat in the presence of itraconazole in healthy participants.

    Number of subjects who experience treatment-emergent adverse events (TEAEs)

    Time frame: Up to 2 months

  2. Safety and tolerability of varegacestat in the presence of itraconazole in healthy participants.

    Number of subjects who experience abnormalities in clinical laboratory tests such as serum chemistry and hematology

    Time frame: Up to 2 months

  3. Safety and tolerability of varegacestat in the presence of itraconazole in healthy participants.

    Number of subjects who experience 12-lead ECG abnormalities

    Time frame: Up to 2 months

  4. Ctrough of itraconazole and hydroxy-itraconazole in combination with varegacestat in healthy participants.

    Ctrough. values on prior to dosing itraconazole

    Time frame: Up to 5 weeks

07

Study locations

1 site
  • Celerion
    Tempe, Arizona 85289, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Dec 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 7, 2024
StartActual
Nov 11, 2024
Primary completionActual
Dec 30, 2024
CompletionActual
May 7, 2025
Last update
May 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06677996
Lead sponsor
Immunome, Inc.
Responsible party
Sponsor
First posted
Nov 7, 2024
Start date
Nov 11, 2024
Primary completion
Dec 30, 2024
Completion
May 7, 2025
Last update
May 11, 2025

Study contacts

Michelle Valentine
principal investigator · Celerion

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BMS-986115 · Itraconazole

Start the discussion